Adverse reaction | Measure |
---|---|
• Absolute neutrophil count < 0.5 × 109/L | • Interrupt dosing until absolute neutrophil count ≥1.5 × 109/L |
• Platelet count < 50 × 109/L | • Interrupt dosing until platelet count ≥75 × 109/L |
• Febrile neutropenia | • Interrupt dosing until toxicity resolves to grade 1 or baseline. • When resuming dosing, decrease the dose level by 5 mg/m2/dose from the previous dose level. • Do not increase dose after it has been reduced. |
• CTCAE v.5 grade 4 neutropenia (< 0.5 × 109/L) or thrombocytopenia (< 25 × 109/L) that results in more than one week’s delay in start of next cycle | |
• CTCAE v.5 non-haematologic grade 3 or grade 4 adverse reaction; except for grade nausea and/or vomiting controlled by antiemetic therapy or diarrhoea responsive to antidiarrhoeal medicinal products |